Streetbeat News

Price Targets

BBY

Evercore ISI Group analyst Greg Melich has maintained an In-Line rating on Best Buy Co (NYSE:BBY) but has lowered the price target from $75 to $70.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 6:27 pm

LOW

Evercore ISI Group analyst Greg Melich has maintained an In-Line rating on Lowe's Companies (NYSE:LOW) and increased the price target from $205 to $210.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 6:25 pm

GDDY

RBC Capital Markets analyst Brad Erickson upgraded GoDaddy Inc (NYSE:GDDY) to Outperform from Sector Perform and increased the price target to $124 from $90. Erickson highlighted GoDaddy's potential to benefit 'outsizedly' from AI tools, which could reduce customer acquisition friction. Despite the web design industry's top-of-funnel trends underperforming, GoDaddy's customer acquisition channel is seen as a tailwind. The analyst also expects cost synergies from workload migration/unification and ties heavy product development investments to potential revenue growth. Revenue and adjusted EBITDA forecasts for FY23 are $4.255 billion and $1.124 billion, and for FY24, $4.61 billion and $1.377 billion, respectively. GoDaddy's Q3 FY23 results exceeded expectations, with revenue of $1.070 billion and EPS of $0.89. Following the news, GDDY shares rose by 2.85% to $95.51.

Portfolio Pulse from Lekha Gupta

November 22, 2023 | 6:19 pm

SIX

Stifel analyst Steve Wieczynski has maintained a Buy rating on Six Flags Entertainment (NYSE:SIX) and increased the price target from $30 to $32.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 6:16 pm

NVDA

Stifel analyst Ruben Roy has reaffirmed a Buy rating on NVIDIA Corporation (NASDAQ:NVDA) and increased the price target from $600 to $665, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 6:14 pm

ARGX

DNTH

SNY

Wedbush initiated coverage on Dianthus Therapeutics Inc (DNTH) with an Outperform rating and a price target of $23, citing the potential of its lead program DNTH103, a monoclonal antibody targeting the complement C1s protein. DNTH103 is advancing in Phase 2 studies, with Phase 1 data showing a meaningful extension of half-life. The generalized myasthenia gravis (gMG) opportunity is highlighted as most attractive. The article also mentions Argenx SE (ARGX) and Sanofi SA (SNY) in the context of supporting the complement-inhibition approach in CIDP. The complement inhibition field is active with three acquisitions in the last three years, indicating a high interest in this therapeutic area. DNTH shares were up 1.14% at $11.50.

Portfolio Pulse from Vandana Singh

November 22, 2023 | 6:12 pm

JACK

Stifel analyst Chris O'Cull has maintained a Hold rating on Jack In The Box (NASDAQ:JACK) but has reduced the price target from $80 to $75.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 6:12 pm

FUN

Stifel analyst Steven Wieczynski has maintained a Buy rating on Cedar Fair (NYSE:FUN) but has reduced the price target from $51 to $49.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 6:10 pm

BRBR

Stifel analyst Matthew Smith has reaffirmed a Buy rating on BellRing Brands (NYSE:BRBR) and increased the price target from $48 to $54, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 6:08 pm

CBRE

CBRE Group (NYSE:CBRE) received 5 analyst ratings in the last quarter with an average price target of $91.0, representing an upside from the current price of $77.9. The ratings include 2 bullish, 2 somewhat bullish, and 1 indifferent. The new average price target is a 4.81% decrease from the previous target of $95.60.

Portfolio Pulse from Benzinga Insights

November 22, 2023 | 6:00 pm